Study of antitumor effectiveness of Ras GTPase peptide inhibitor (Inh-Ras) in xenograft model of non-small cell lung cancer

In recent years, treatment of tumors associated with the RAS oncogene has become an important problem. High level of mutations in this gene is characteristic of tumors of various locations which makes it an attractive target. Modern drugs selectively inhibiting mutant KRAS have significant benefits compared to traditional treatment methods but also have shortcomings including high rate of adverse events. Therefore, development of new drugs – Ras GTPase inhibitors – with better pharmacodynamics characteristics is an important task.
Aim. To study in vivo specific pharmacological activity of a new peptide inhibitor of Ras GTPase (Inh-Ras) in a xenograft model of human non-small cell lung cancer.
Statistically significant data on increased lifespan of mice who were administered Ras GTPase inhibitor compared to the control group were obtained: by 16 % for dose 5 mg/kg and by 36.3 % for dose 10 mg/kg. Additionally, dose-dependent slowing of tumor growth by 30.5 and 57.3 %, respectively, was observed. High specificity due to the mechanism of action of the peptide construct allows to anticipate minimization of side effects of the potential drug Inh-Ras.

1. Prior I.A., Hood F.E., Hartley J.L. The frequency of Ras mutations in cancer. Cancer Res 2020;80(14):2969–74. DOI: 10.1158/0008-5472.can-19-3682

2. Simanshu D.K., Nissley D.V., McCormick F. RAS proteins and their regulators in human disease. Cell 2017;170(1):17–33. DOI: 10.1016/j.cell.2017.06.009

3. Kleeff J., Korc M., Apte M. et al. Pancreatic cancer. Nat Rev Dis Primers 2016;16022. DOI: 10.1038/nrdp.2016.22

4. Bray F., Laversanne M., Sung H. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74(3):229–63. DOI: 10.3322/caac.21834

5. Hudson A., Chan C., Woolf D. et al. Is heterogeneity in stage 3 non-small cell lung cancer obscuring the potential benefits of doseescalated concurrent chemo-radiotherapy in clinical trials? Lung Cancer 2018;118:139–47. DOI: 10.1016/j.lungcan.2018.02.006

6. Pöttgen C., Eberhardt W., Stamatis G. et al. Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC) - a cumulative meta-analysis of the randomized evidence. Oncotarget 2017;8(25):41670–8. DOI: 10.18632/oncotarget.16471

7. Kulinich T.M., Ivanov A.V., Zakharenko M.V. et al. Internalized peptides (cell-penetrating peptides, Cps) and the possibilities of their therapeutic use. Vestnik Rossiyskogo nauchnogo tsentra rentgenoradiologii = Bulletin of the Russian Scientific Center of Radiology 2020;20(4):106–26. (In Russ.).

8. Bozhenko V.K., Goncharov S.V., Kudinova E.A. et al. Safety assessment with the establishment of the maximum tolerated dose of RAS-GTPase inhibitor (Ing-Ras) for the treatment of tumors of the gastrointestinal tract: preliminary results of study I. Al’manah klinicheskoy meditsiny = Almanac of Clinical Medicine 2023;51(7):376–96. (In Russ.). DOI: 10.18786/2072-0505-2023-51-045

9. Kulinich T.M., Ivanov A.V., Bolshakova O.B. et al. To study the specific pharmacological activity of the Ras-GTPase peptide inhibitor sequence in vitro. Vestnik Rossiyskogo nauchnogo tsentra rentgenoradiologii = Bulletin of the Russian Scientific Center of Radiology 2022;22(4):347–60. (In Russ.).

10. Kulinich T.M., Shishkin A.M., Ivanov A.V. et al. To study the antitumor properties of a peptide construct, including an internalized sequence and a Ras-GTPase inhibitor, in relation to colon cancer (HT29) and ovarian cancer (OAW-42, OVCAR-3) cell lines. Vestnik Rossiyskogo nauchnogo tsentra rentgenoradiologii = Bulletin of the Russian Scientific Center of Radiology 2021;21(4):100–20. (In Russ.).

11. American Type Culture Collection (ATCC): cell products/human cells/CRM-CCL-185. Available at: https://www.atcc.org/products/crm-ccl-185/.

12. Laktionov K.K., Sarantseva K.A., Nelyubina L.A. et al. KRAS-mutated non-small cell lung cancer: new treatment strategies. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology 2024;23(2):72–81. DOI: 10.21294/1814-4861-2024-23-2-72-81

13. Amgen Inc. LUMAKRAS™ (sotorasib) tablets, for oral use: US prescribing information. 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf.

14. Jänne P.A., Riely G.J., Gadgeel S.M. et al. Adagrasib in non-smallcell lung cancer harboring a KRAS G12C mutation. New Engl J Med 2022;387(2):120–31. DOI: 10.1056/nejmoa2204619